Table 2. (Continued)

<table>
  <tr>
    <th rowspan="2">Cell line</th>
    <th colspan="10">PKC isoform</th>
    <th rowspan="2">Detection *</th>
    <th rowspan="2">Reference</th>
  </tr>
  <tr>
    <th>α</th>
    <th>βI/βII</th>
    <th>γ</th>
    <th>δ</th>
    <th>ε</th>
    <th>η</th>
    <th>θ</th>
    <th>ζ</th>
    <th>λ/ι</th>
  </tr>
  <tr>
    <td>WM115 (primary)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[36]</td>
  </tr>
  <tr>
    <td>WM1205Lu (metastatic)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[36]</td>
  </tr>
  <tr>
    <td>SK-Mel 28 (metastatic)</td>
    <td>+</td>
    <td>–</td>
    <td>–</td>
    <td>+</td>
    <td>+</td>
    <td>ND</td>
    <td>+</td>
    <td>+</td>
    <td>ND</td>
    <td>W, R</td>
    <td>[29]</td>
  </tr>
  <tr>
    <td>A375 (primary)</td>
    <td>+</td>
    <td>–</td>
    <td>–</td>
    <td>+</td>
    <td>+</td>
    <td>ND</td>
    <td>+</td>
    <td>+</td>
    <td>ND</td>
    <td>W, R</td>
    <td>[29]</td>
  </tr>
  <tr>
    <td>Murine</td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>B16 (metastatic)</td>
    <td>+</td>
    <td>–</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>N</td>
    <td>[37]</td>
  </tr>
  <tr>
    <td>B16-F1 (metastatic)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[38]</td>
  </tr>
  <tr>
    <td>B16 (metastatic)</td>
    <td>+</td>
    <td>–</td>
    <td>–</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>N</td>
    <td>[39]</td>
  </tr>
  <tr>
    <td>B16 (metastatic)</td>
    <td>+</td>
    <td>–</td>
    <td>–</td>
    <td>–</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[30]</td>
  </tr>
  <tr>
    <td>B16 (metastatic)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[40]</td>
  </tr>
  <tr>
    <td>B16 (metastatic)</td>
    <td>+</td>
    <td>–</td>
    <td>–</td>
    <td>+</td>
    <td>+</td>
    <td>ND</td>
    <td>+</td>
    <td>+</td>
    <td>W</td>
    <td>[41]</td>
  </tr>
  <tr>
    <td>B16 (metastatic)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[42]</td>
  </tr>
  <tr>
    <td>B16 (metastatic)</td>
    <td>+</td>
    <td>+</td>
    <td>+</td>
    <td>+</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[43]</td>
  </tr>
  <tr>
    <td>B16 (metastatic)</td>
    <td>+</td>
    <td>–</td>
    <td>–</td>
    <td>+</td>
    <td>–</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[44]</td>
  </tr>
  <tr>
    <td>B16-BL6 (metastatic)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[45]</td>
  </tr>
  <tr>
    <td>B16-BL6 (metastatic)</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>–</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[46]</td>
  </tr>
</table>

* N: Northern blot, F: Flow cytometry, W: Western blot, R: Reverse transcription-polymerase chain reaction.
** Not determined.

the β isoform in melanocytes [49], and further showed that PKC inhibitor reduces pigmentation in murine skin in vivo [50]. It is interesting to assume that the β isoform is indispensable for the regulation of the tyrosinase activity, but melanin is detected even in the melanoma cells lacking the PKC β isoform [25,27]. On the other hand, the α isoform is increased in murine B16 melanoma cells treated with retinoic acid [37,39], and the induction as well as the overexpression of this PKC isoform enhances the melanin synthesis, suggesting the involvement of the α isoform in melanogenesis [38]. The level of the α isoform is also elevated in B16 cells cultured with mannosylerythritol lipid, a novel extracellular glycolipid from yeast that induces differentiation of HL-60 promyelocytic leukemia cells [44]. The introduction of antisense oligodeoxynucleotides against the α isoform prevented mannosylerythritol lipid-induced melanogenesis, and the expression of the

Table 3. The expression of PKC isoforms in human melanoma cells in vivo

<table>
  <tr>
    <th rowspan="2">Origin</th>
    <th colspan="10">PKC isoform</th>
    <th rowspan="2">Detection**</th>
    <th rowspan="2">Reference</th>
  </tr>
  <tr>
    <th>Clinical type*</th>
    <th>α</th>
    <th>βI/βII</th>
    <th>γ</th>
    <th>δ</th>
    <th>ε</th>
    <th>η</th>
    <th>θ</th>
    <th>ζ</th>
    <th>λ/ι</th>
  </tr>
  <tr>
    <td>Primary</td>
    <td>ALM</td>
    <td>+</td>
    <td>–</td>
    <td>–</td>
    <td>+</td>
    <td>+</td>
    <td>ND**</td>
    <td>ND</td>
    <td>+</td>
    <td>ND</td>
    <td>W</td>
    <td>[25]</td>
  </tr>
  <tr>
    <td>Metastatic</td>
    <td>Unknown</td>
    <td>+</td>
    <td>–</td>
    <td>–</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>W</td>
    <td>[25]</td>
  </tr>
  <tr>
    <td>Metastatic</td>
    <td>NS (5 cases)</td>
    <td>ND</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>I</td>
    <td>[27]</td>
  </tr>
  <tr>
    <td>Metastatic</td>
    <td>NS (5 cases)</td>
    <td>ND</td>
    <td>–</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>I</td>
    <td>[27]</td>
  </tr>
  <tr>
    <td>Metastatic</td>
    <td>SSM</td>
    <td>+</td>
    <td>–</td>
    <td>+</td>
    <td>+</td>
    <td>–</td>
    <td>+</td>
    <td>+</td>
    <td>W</td>
    <td>[28]</td>
  </tr>
  <tr>
    <td>Metastatic</td>
    <td>NS (5 cases)</td>
    <td>+</td>
    <td>–</td>
    <td>+</td>
    <td>+</td>
    <td>–</td>
    <td>+</td>
    <td>W</td>
    <td>[28]</td>
  </tr>
  <tr>
    <td>Metastatic</td>
    <td>ALM (2 cases)</td>
    <td>+</td>
    <td>–</td>
    <td>+</td>
    <td>+</td>
    <td>–</td>
    <td>+</td>
    <td>W</td>
    <td>[28]</td>
  </tr>
  <tr>
    <td>Primary</td>
    <td>ALM</td>
    <td>–</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>I</td>
    <td>[36]</td>
  </tr>
  <tr>
    <td>Primary</td>
    <td>ALM (11 cases)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>I</td>
    <td>[36]</td>
  </tr>
  <tr>
    <td>Primary</td>
    <td>SSM (7 cases)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>I</td>
    <td>[36]</td>
  </tr>
  <tr>
    <td>Metastatic</td>
    <td>ALM (2 cases)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>I</td>
    <td>[36]</td>
  </tr>
  <tr>
    <td>Metastatic</td>
    <td>SSM (2 cases)</td>
    <td>+</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>ND</td>
    <td>I</td>
    <td>[36]</td>
  </tr>
</table>

*ALM: acral lentiginous melanoma; SSM: superficial spreading melanoma, NS: not stated.
**W: Western blot; I: immunohistochemistry.
***Not determined.